Early PSA Change after [(177)Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival

SIMPLE SUMMARY: Radioligand therapy with [(177)Lu]PSMA-617 (PSMA-RLT) is a promising therapeutic option for metastatic castration-resistant prostate cancers (mCRPC), as its clinical relevance has recently been confirmed in the phase III VISION-trial. As prostate-specific antigen (PSA) plays an impor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kind, Felix, Fassbender, Thomas F., Andrieux, Geoffroy, Boerries, Melanie, Meyer, Philipp T., Ruf, Juri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750166/
https://www.ncbi.nlm.nih.gov/pubmed/35008315
http://dx.doi.org/10.3390/cancers14010149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750166/
https://www.ncbi.nlm.nih.gov/pubmed/35008315
http://dx.doi.org/10.3390/cancers14010149

Ejemplares similares